Kaposi's sarcoma (Treatment)

Daunoxome NDA Approved as First Line Therapy for KS

Published in AIDS Weekly, April 22nd, 1996

NeXstar Pharmaceuticals, Inc., Boulder, Colorado, announced that the U.S. Food and Drug Administration (FDA) has approved the company's new drug applications (NDA) for the anticancer drug DaunoXome (daunorubicin citrate liposome injection), as a first-line cytotoxic therapy for the treatment of advanced, HIV associated Kaposi's sarcoma (KS).

NeXstar plans to launch DaunoXome shortly at a price competitive with conventional therapy.

DaunoXome is formulated to maximize the selectivity of daunorubicin for solid tumors in the body. In granting approval for DaunoXome, the FDA noted that the drug was as effective as the current three-drug regimen of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry